PHM 111 Week 1

Injured tissues release thromboplastin, a substance that triggers the clotting mechanism.

• Inhibition of performed clotting factors (Heparin)
• Prevention of synthesis of normal clotting factors( Coumadin derivatives)
• Therapy is focused on preventing intravascular thrombosis by decreasing blood coagulability

• Prevention of venous thrombosis
• colt suppression prior to blood transfusions

Major ADR for both types of drugs are hemorrhage

• Partial Thromboplastin Time (PPT)
• Measures the function of the intrinsic and common pathways that are affected by heparin.

• Heparin
• Low Molecular Weight Heparins
• Warfarin

• Inhibits thrombin activity so that fibrin cannot be formed
• Derived from pork and beef lungs and intestinal tissue
• Dose titrated according to PTT
• Antidote is protamine sulfate

• Are smaller and have lower molecular weight than heparin
• Same mechanism of action as heparin
• Longer half-life than heparin
• Given SC
• Less lab monitoring required
• Fragmin & Lovenox CAN NOT be used interchangeably (unit for unit) with each other or with heparin.

• Does not affect established clots, but does prevent further extension of formed clots
• Indicated for prophylaxis and treatment of deep vein thrombosis and pulmonary thromboembolism
• Also used for prophylaxis of thromboembolism associated with a trial fibrillation or myocardial infraction
• Dose id titrated based on target INR (International Normalized Ration)

Crosses placenta and causes hemorrhage in fetus.

Vitamin K